"How long does crizotinib work? a rare case of recurrent inflammatory myofibroblastic tumor"

Albayrak H. C., Gürler F., Sütçüoğlu O., Akyürek N., Özet A.

Anti-Cancer Drugs, cilt.33, sa.1, ss.109-111, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1097/cad.0000000000001137
  • Dergi Adı: Anti-Cancer Drugs
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.109-111
  • Anahtar Kelimeler: anaplastic lymphoma kinase, crizotinib, inflammatory myofibroblastic tumors, mesenchymal solid tumors, PSEUDOTUMOR, DIAGNOSIS
  • Gazi Üniversitesi Adresli: Evet

Özet

Inflammatory myofibroblastic tumors (IMTs) are mesenchymal solid tumors, in which anaplastic lymphoma kinase (ALK) gene rearrangement might be detected. A 48-year-old female presented with IMT of lung, treated with surgery. After a 39-month disease-free survival metastatic recurrence was occurred involving soft tissues both infra- and supradiaphragmatic regions. The biopsies obtained from metastatic regions confirmed the recurrence with ALK rearrangement in immunohistochemistry. Initial partial response observed early in treatment course remained as a stable disease with crizotinib treatment. Although an excellent outcome with overall survival of 57 months was observed in our case, there is not enough information about survivals with crizotinib and the treatment options beyond progression. Therefore, every individual case has a unique value paving the way for more effective treatment.